Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer

Summary

Eligible patients was assigned in a 1:1 ratio to receive either low-dose capecitabine maintenance (intervention group) which is newly diagnostic to be planned to receive capecitabine after finishing the standard adjuvant treatment or observation (control group) within 4 weeks after completion of standard adjuvant chemotherapy.

Timeline

Start

2021-11-01

Primary completion

2024-12-30

Completion

2025-05-30

Drugs

Indications